CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Lisdexamfetamine Dimesylate Tablet, Chewable
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2023-07-14. Latest FDA row update: 2026-09-18.
FDA lists 18 package records, with companies: Novadoz Pharmaceuticals LLC, Sun Pharmaceutical Industries, Inc., Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA Inc.. Package NDCs: 57664-083-88, 57664-084-88, 57664-085-88, 57664-086-88, 57664-087-88, 57664-088-88, 59417-115-01, 59417-116-01, 59417-117-01, 59417-118-01, 59417-119-01, 59417-120-01, 72205-132-91, 72205-133-91, 72205-134-91, 72205-135-91, 72205-136-91, 72205-137-91.
FDA shortage reason: Not stated in the grouped FDA source rows.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Novadoz Pharmaceuticals LLC | 72205-132-91 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91) | Available | 2026-09-16 |
| Novadoz Pharmaceuticals LLC | 72205-133-91 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91) | Available | 2026-09-16 |
| Novadoz Pharmaceuticals LLC | 72205-134-91 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91) | Available | 2026-09-16 |
| Novadoz Pharmaceuticals LLC | 72205-135-91 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91) | Available | 2026-09-16 |
| Novadoz Pharmaceuticals LLC | 72205-136-91 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91) | Available | 2026-09-16 |
| Novadoz Pharmaceuticals LLC | 72205-137-91 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91) | Available | 2026-09-16 |
| Sun Pharmaceutical Industries, Inc. | 57664-083-88 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88) | Available | 2026-09-18 |
| Sun Pharmaceutical Industries, Inc. | 57664-084-88 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88) | Available | 2026-09-18 |
| Sun Pharmaceutical Industries, Inc. | 57664-085-88 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88) | Available | 2026-09-18 |
| Sun Pharmaceutical Industries, Inc. | 57664-086-88 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88) | Available | 2026-09-18 |
| Sun Pharmaceutical Industries, Inc. | 57664-087-88 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88) | Available | 2026-09-18 |
| Sun Pharmaceutical Industries, Inc. | 57664-088-88 | Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88) | Available | 2026-09-18 |
| Takeda Pharmaceuticals USA Inc. | 59417-115-01 | Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01) | Available | 2026-09-15 |
| Takeda Pharmaceuticals USA Inc. | 59417-116-01 | Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01) | Available | 2026-09-15 |
| Takeda Pharmaceuticals USA Inc. | 59417-117-01 | Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01) | Available | 2026-09-15 |
| Takeda Pharmaceuticals USA Inc. | 59417-118-01 | Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01) | Available | 2026-09-15 |
| Takeda Pharmaceuticals USA Inc. | 59417-119-01 | Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01) | Available | 2026-09-15 |
| Takeda Pharmaceuticals USA Inc. | 59417-120-01 | Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01) | Available | 2026-09-15 |
Source facts
Grouped generic ingredient: Lisdexamfetamine Dimesylate Tablet, Chewable · 18 package records
Therapeutic categories: Psychiatry
Dosage forms: Tablet, Chewable
Routes: ORAL
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.